ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0112

A Randomized Trial Showing No Differences in Patient Satisfaction with Telemedicine Delivered by Phone or Video During COVID-19 in Rheumatology and Other Medical Specialty Clinics
Abstract Number: 0441

A Randomized, Double-blind, Placebo-controlled Study of Arimoclomol in Patients with Inclusion Body Myositis
Abstract Number: L10

A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease
Abstract Number: 0819

A Real-World 2-Year Prospective Study of Medication Tapering in Patients with RA in Sustained Remission in the RHEUmatoid Arthritis Medication TAPering (RHEUMTAP) Cohort
Abstract Number: 0805

A Real-world Prospective Observational Study of the Effectiveness of Golimumab in Adult Greek Patients with RA, PsA and Axial SpA and Inadequate Response to Initial TNFα Inhibitor Therapy
Abstract Number: 0047

A Role for Neutrophils in Disease Onset and Severity of Spondyloarthritis
Abstract Number: 0196

A Single Center, Double Blind, Randomized, Placebo-Controlled Trial of Anakinra in Adult Patients with Features of Cytokine Storm Syndrome in COVID-19
Abstract Number: 0945

A Single-cell Atlas of Human Synovial Endothelial Cells in Inflammatory Arthritis
Abstract Number: 0656

A Survey Based Descriptive Study to Assess the Quality of Sleep in Rheumatic Patients
Abstract Number: 1164

A Survey of Treatment Satisfaction with Intravenous Immunoglobulin Among Patients with Inflammatory Myositis
Abstract Number: 1207

A Systematic Review Looking at the Relationship Between Serum Calprotectin and Ultrasound Parameters in Rheumatoid Arthritis
Abstract Number: 0384

A Tough Cell: The Argument for a Biomarker of Clinical and Imaging Outcomes in Spondyloarthritis: The Neutrophil Lymphocyte Ratio and the Platelet Lymphocyte Ratio
Abstract Number: 1721

A Womb with Rheum: Women’s Health Providers’ Confidence and Educational Needs in the Care of Those with Rheumatic Diseases
Abstract Number: 1250

Abatacept and Other DMARDs Have Common Transcriptomic Effects on RA Synovial Tissue
Abstract Number: 1683

Abatacept in Usual and in Non-Specific Interstitial Pneumonia Associated to Rheumatoid Arthritis. National Multicenter Study of 190 Patients

« Previous Page
1
…
3
4
5
6
7
…
132
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].